(Q43634902)

25 November 2017

title

An α-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine (English)

1 reference

25 November 2017

0 references

7

1 reference

25 November 2017

Yoon-Sook Lee

1

1 reference

25 November 2017

Kyoo-A Lee

2

1 reference

25 November 2017

Jae-Young Lee

3

1 reference

25 November 2017

Min-Hee Kang

4

1 reference

25 November 2017

You Chan Song

5

1 reference

25 November 2017

Dong Jae Baek

6

1 reference

25 November 2017

Chang-Yuil Kang

8

1 reference

25 November 2017

language of work or name

English

0 references

publication date

16 November 2010

1 reference

25 November 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

25 November 2017

volume

29

1 reference

25 November 2017

issue

3

1 reference

25 November 2017

page(s)

417-425

1 reference

The genesis of a pandemic influenza virus.

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

Emergence and pandemic potential of swine-origin H1N1 influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

Vaccines for seasonal and pandemic influenza.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

Mucosal immunity and vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

Mucosal vaccines: the promise and the challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

7 January 2021

The biology of NKT cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

NKT cells: what's in a name?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

Adjuvant activity mediated by iNKT cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

Harnessing invariant NKT cells in vaccination strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

Mechanism of NKT cell activation by intranasal coadministration of alpha-galactosylceramide, which can induce cross-protection against influenza viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

A pegylated derivative of alpha-galactosylceramide exhibits improved biological properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

Immunotherapeutic potential for ceramide-based activators of iNKT cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

A modified alpha-galactosyl ceramide for staining and stimulating natural killer T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

Rational design and evaluation of a branched-chain-containing glycolipid antigen that binds to CD1d

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

Ginseng and Salviae herbs play a role as immune activators and modulate immune responses during influenza virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

Alpha-galactosylceramide: potential immunomodulatory activity and future application

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

The regulatory role of Valpha14 NKT cells in innate and acquired immune response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

Natural killer T cells: an unconventional T-cell subset with diverse effector and regulatory functions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

Mediastinal lymph node CD8alpha- DC initiate antigen presentation following intranasal coadministration of alpha-GalCer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

CD1d-restricted T cells license B cells to generate long-lasting cytotoxic antitumor immunity in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.005

10.1016/J.VACCINE.2010.11.005

7 January 2021

Identifiers

DOI

1 reference

release_p43yvjval5gszp2opkcidstwi4

25 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/p43yvjval5gszp2opkcidstwi4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference